Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases

doi:10.1038/s41388-020-01613-4

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23655

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23655

题名:	Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases
作者:	Liu, PI;Chang, AC;Lai, JL;Lin, TH;Tsai, CH;Chen, PC;Jiang, YJ;Lin, LW;Huang, WC;Yang, SF;Tang, CH
日期:	2021
上传时间:	2022-08-05T09:40:46Z (UTC)
出版者:	SPRINGERNATURE
ISSN:	0950-9232
摘要:	Cancer-related bone erosion occurs frequently in bone metastasis and is associated with severe complications such as chronic bone pain, fractures, and lower survival rates. In recognition of the fact that the darkness hormone melatonin is capable of regulating bone homeostasis, we explored its therapeutic potential in bone metastasis. We found that melatonin directly reduces osteoclast differentiation, bone resorption activity and promotes apoptosis of mature osteoclasts. We also observed that melatonin inhibits RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevents cancer-associated osteoclast differentiation. In lung and prostate bone metastasis models, twice-weekly melatonin treatment markedly reduced tumor volumes and numbers of osteolytic lesions. Melatonin also substantially lowered the numbers of TRAP-positive osteoclasts in tibia bone marrow and RANKL expression in tumor tissue. These findings show promise for melatonin in the treatment of bone metastases.
URI:	http://dx.doi.org/10.1038/s41388-020-01613-4 https://www.webofscience.com/wos/woscc/full-record/WOS:000607998600005 https://ir.csmu.edu.tw:8080/handle/310902500/23655
關聯:	ONCOGENE ,2021,v40,issue 8, P1503-1515
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	218	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....